Immunotherapy combination approaches: mechanisms, biomarkers and clinical observations
LH Butterfield, YG Najjar - Nature Reviews Immunology, 2024 - nature.com
The approval of the first immune checkpoint inhibitors provided a paradigm shift for the
treatment of malignancies across a broad range of indications. Whereas initially, single …
treatment of malignancies across a broad range of indications. Whereas initially, single …
LAG-3 as the third checkpoint inhibitor
Abstract Lymphocyte activation gene 3 (LAG-3) is an inhibitory receptor that is highly
expressed by exhausted T cells. LAG-3 is a promising immunotherapeutic target, with more …
expressed by exhausted T cells. LAG-3 is a promising immunotherapeutic target, with more …
Neoadjuvant relatlimab and nivolumab in resectable melanoma
RN Amaria, M Postow, EM Burton, MT Tetzlaff, MI Ross… - Nature, 2022 - nature.com
Relatlimab and nivolumab combination immunotherapy improves progression-free survival
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …
over nivolumab monotherapy in patients with unresectable advanced melanoma. We …
Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma
Background Lymphocyte-activation gene 3 (LAG-3) and programmed death 1 (PD-1) are
distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination …
distinct inhibitory immune checkpoints that contribute to T-cell exhaustion. The combination …
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
AJ Korman, SC Garrett-Thomson… - Nature Reviews Drug …, 2022 - nature.com
Cancer immunity, and the potential for cancer immunotherapy, have been topics of scientific
discussion and experimentation for over a hundred years. Several successful cancer …
discussion and experimentation for over a hundred years. Several successful cancer …
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
The discovery and clinical implementation of immune-checkpoint inhibitors (ICIs) targeting
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the …
CTLA4, PD-1 and PD-L1 has revolutionized the treatment of cancer, as recognized by the …
T cells specific for α-myosin drive immunotherapy-related myocarditis
Immune-related adverse events, particularly severe toxicities such as myocarditis, are major
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …
challenges to the utility of immune checkpoint inhibitors (ICIs) in anticancer therapy. The …
LAG-3 and PD-1 synergize on CD8+ T cells to drive T cell exhaustion and hinder autocrine IFN-γ-dependent anti-tumor immunity
Overcoming immune-mediated resistance to PD-1 blockade remains a major clinical
challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined …
challenge. Enhanced efficacy has been demonstrated in melanoma patients with combined …
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
L Cai, Y Li, J Tan, L Xu, Y Li - Journal of hematology & oncology, 2023 - Springer
In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted …
Exploring the NK cell platform for cancer immunotherapy
JA Myers, JS Miller - Nature reviews Clinical oncology, 2021 - nature.com
Natural killer (NK) cells are cytotoxic lymphocytes of the innate immune system that are
capable of killing virally infected and/or cancerous cells. Nearly 20 years ago, NK cell …
capable of killing virally infected and/or cancerous cells. Nearly 20 years ago, NK cell …